DGAP-Adhoc: SynBiotic SE: Majority takeover of hemp industry pioneer Daniel Kruse's group of companies as part of a capital increase in kind
DGAP-Ad-hoc: SynBiotic SE / Key word(s): Takeover Insider information pursuant to Article 17 MAR (Ad hoc announcement) NOT FOR PUBLICATION OR DISTRIBUTION, WHETHER DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN, OR WITHIN OR TO ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED. FURTHER RESTRICTIONS APPLY. SynBiotic SE: Majority takeover of hemp industry pioneer Daniel Kruse's group of companies as part of a capital increase in kind EIHA President Daniel Kruse and industry pioneer Rafael Dulon bring a combined half a century of cannabis expertise to SynBiotic SE. With the four companies Hanf Farm GmbH (largest organic hemp cultivation firm in Europe), Hempro International GmbH (largest hemp food distributor in Central Europe, with an international supplier and customer network, and profitable own brands), Hemp Factory GmbH (largest hemp food production in Central Europe) and MH medical hemp GmbH (CBD expert and wholesaler with THC BtM approval), SynBiotic SE's portfolio is being enriched by important infrastructures and profitable brands. About SynBiotic SE SynBiotic SE is the largest listed group in Europe in the hemp and cannabis sector and pursues an EU-focused buy & build investment strategy. The group of companies covers the entire supply chain from cultivation to production to retail - from field to shelf. One of the company's core businesses is the research & development, production and marketing of cannabinoid- and terpene-based solutions to major societal problems such as pain, sleep and anxiety. In doing so, SynBiotic SE is active not only in the dietary supplement and cosmetics markets, but also in the medical and, in the future, recreational cannabis sector. Further information can be found at https://www.synbiotic.com Investor relations Important information Subject to certain exemptions under the Securities Act, the securities referred to in this announcement may not be offered or sold in Australia, Canada or Japan, or to or for the account of any person resident or living in Australia, Canada or Japan. This release contains forward-looking statements that are subject to certain risks and uncertainties. Future results may differ considerably from those currently anticipated, due to various risk factors and contingencies such as changes in business, economic and competitive conditions, exchange rate fluctuations, uncertainties regarding litigation or investigative proceedings, and the availability of financial resources. SynBiotic SE assumes no responsibility to update the forward-looking statements contained in this release.
30-Nov-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | SynBiotic SE |
Barer Str. 7 | |
80333 München | |
Germany | |
E-mail: | [email protected] |
Internet: | https://www.synbiotic.com/ |
ISIN: | DE000A3E5A59 |
WKN: | A3E5A5 |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Tradegate Exchange |
EQS News ID: | 1252950 |
End of Announcement | DGAP News Service |
|
1252950 30-Nov-2021 CET/CEST